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infections, although the incidence of symptomatic infections in the older age
classes does increase. The impact of the different assumptions used in the model
was in general limited. CONCLUSIONS: We conclude that over a wide range of
assumptions, an additional booster dose can reduce the incidence of pertussis in
the population.
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OBJECTIVES: To investigate doctors’ perceptions towards factors underlying irra-
tional prescribing practices in treatment of malaria in Pakistan.METHODS:A qual-
itative study with snowball sampling technique was used to identify nineteen
doctors working at hospitals in Islamabad and Rawalpindi. Semi-structured inter-
views were conducted with the doctors until the point of saturation was obtained.
The interviews, which were audio-taped and transcribed verbatim, were evaluated
by thematic content analysis and by other authors’ analysis. RESULTS: Thematic
content analysis identified three major themes and several subthemes: 1) Factors
responsible for irrational prescribing practices in treatment of malaria; 2) Lack of
implementation of standard malaria treatment guidelines in the country; and 3)
Strategies to improve irrational prescribing practices in treatment of malaria. All
the doctors agreed on lack of implementation of standard guidelines in treatment
of malaria while mixed responses were observed regarding factors influencing
rational prescribing. Influence of pharmaceutical industry and unsupervised poly-
therapy were cited as major determinants for irrational prescribing practices in
case of malaria. CONCLUSIONS: The findings suggest that the doctors in Pakistan
are aware of irrational prescribing practices and its consequences in treatment of
malaria but are facing significant barriers in terms of improving the current pre-
scribing practices. There is an urgent need to design strategies such as implemen-
tation of standard malaria treatment guidelines, revision of health policies and up
gradation of education and training of health players in order to improve the cur-
rent prescribing practices for antimalarials.
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OBJECTIVES: Every winter season an influenza epidemic occurs, although strength
and duration may vary. In 2006-2007 in Austria presumably 5% of the whole pop-
ulation fell sick while 21% of age 15 and above were vaccinated. The goal was to
build an agent based model to understand, model and simulate the progress of
influenza epidemics. METHODS: The agent based model simulates single persons
with an infection state (susceptible, infected with or without symptoms, resistant,
vaccinated). Based on the results of a wide European study (POLYMOD, EC-Project
SP22-CT-2004-502084) people have contacts in different places like housholds,
schools or workplaces. Transmissions are possible upon contacts, then a person is
infected for a while until he or she becomes resistant upon recovery. RESULTS: The
outbreak of the epidemic starts when a few people are initially infected while the
rest is susceptible or vaccinated. After some time the epidemic stops due to a larger
number of resistant and a smaller number of susceptible people. Since only 5% of
the population fall sick the situations at outbreak and at termination of the epi-
demic are similar and therefore it behaves very sensitive to parameter changes.
CONCLUSIONS: Some parameter changes in the model can be interpreted as inter-
ventions in reality. But usually the influenza does not react sensitive to interven-
tions. For example, an increase of the vaccination rate by 5% prevents an outbreak
of the epidemic in the model which is obviously not true. This insight has two
consequences: First, the influenza does not just spread and stop by transmission
and recovery of people. There must be one or more other impacts modulating
outbreaks like predestined people to fall sick or the climate. Second, without
knowledge of these impacts it is almost impossible to predict the effect of vacci-
nation strategies exactely.
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OBJECTIVES: In 1996, the Brazilian government implemented a universal access
program for anti-retroviral drugs to improve the treatment of HIV/AIDS. A recent
study showed $1.78 billion USD savings from the program compared to pricing in
the US. This study estimates the drug costs saved in 2010 by the program’s imple-
mentation compared to pricing in Canada and Australia. METHODS: Nationwide
drug distribution data and drug prices for the Brazilian government’s antiretroviral
access program were obtained for 2010 from the Ministry of Health data. Drug
prices for each drug were converted to daily dosage costs in US dollars. Comparable
government drug prices were obtained for Ontario, Canada and Australia. The
Brazilian, Canadian, and Australian unit drug costs were multiplied by the distri-
bution rates in Brazil to calculate and compare the cost of the Brazilian 2010 drug
distribution using the Brazilian and Canadian/Australian pricing rates. Any cost
savings to the Brazilian government were also calculated. The savings calculation
assumes that the Brazilian government has paid for all of the drugs distributed
regardless of patient utilization rates. Sensitivity analysis was conducted on the
distribution rates, pricing, and utilization rates. RESULTS: The Brazilian govern-
ment saved $448.1 million USD in and $403.1 million USD 2010 versus Canada and
Australia, respectively through its pricing program. The total cost of the drugs
distributed was $1.94 billion with the Brazilian pricing. This compares to $2.37bil-
lion and $2.41 billion dollars using Canadian and Australian pricing rates, respec-
tively. Sensitivity analysis found the results to be stable. CONCLUSIONS: Signifi-
cant costs savings have been realized by the Brazilian government through its drug
pricing program. These costs savings should be included as part of any analysis of
the overall impact of the program.
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OBJECTIVES: Childhood prevention programs are important and imperative public
health initiatives. However, prevention programs are often associated with consid-
erable investments. This budget impact analysis was undertaken to position the
Italian investment for a program to prevent respiratory syncytial virus (RSV) con-
sequences in high-risk infants using palivizumab. This prevention program is com-
pared to an existing immunization program in the Lombardy region of Italy: Hu-
man Papillomavirus Vaccine [Types 6, 11, 16, 18] (HPV), considered standard of
care. METHODS: Two budget impact models were developed to assess the impact
of two different programs on Regional Health Service (RHS) expenditure: the budget
impact of RSV prophylaxis program was compared with a non-prophylaxis pro-
gram, while the budget impact of HPV active prophylaxis was compared with a
non-prophylaxis approach. Only direct costs based on disease prevalence, and
program efficacy were included. The model includes RSV prophylaxis administra-
tion costs, RSV-related resource consumption (visits, long term sequelae) and RSV
hospitalization over one year; for HPV prevention program, one year prophylaxis
was assessed against 5 years disease costs due to the low incidence of HPV related
disease in 1 year. Eligible subjects were preterm and high-risk infants (as estab-
lished by national guidelines) for RVS program and all 12-year-old girls cohort for
HPV program. RESULTS: RSV prophylaxis expenditure was estimated at
€11,577,776 in the prophylaxis program arm versus €5,206,534 in the ‘without pro-
phylaxis program’ arm, while for HPV prevention program, vaccination program
expenditure (including vaccine cost) would be 13,068,025€ vs. 356,385€ in no-vac-
cine arm. The net budgetary impact was calculated at €6.4 million for RSV vs. €12.7
million for HPV vaccination. CONCLUSIONS: Considering the RHS perspective, the
budget impact of palivizumab had lower program costs and higher disease cost
offsets vs. HPV vaccination program, positioning its economic value well within the
parameters of cost-effective childhood prevention programs.
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OBJECTIVES: To investigate whether patient reported outcomes could detect dif-
ferences between H1N1 and seasonal influenza vaccinations on resource utilisa-
tion and time off work over a 26 week follow up period. METHODS: In this evalua-
tion, PROBE methodology consisting of a web-based system supplemented by
telephone reporting was used to collect naturalistic data from people who had
received an influenza vaccination during 2009-2010 season. People were recruited
through media advertising and awareness campaigns in public places and work
(West of Scotland). Data collection on day of immunisation, after 3 days, 8 days, 6
weeks, 12 weeks and 26 weeks. Data included baseline demographics, any side
effects following vaccination including the duration/ resource use and time off
work. RESULTS: A total of 1103 vaccine recipients participated in the evaluation.
Overall, 42% of respondents reported experiencing any side effect after vaccination
(excluding pain/discomfort at site of injection) with more people reporting a side
effect with H1N1 vaccination (45% versus 26% seasonal flu vaccination versus 42%
receiving both vaccines p0.001). However, there was no significant difference in
health service utilisation between the groups – 5.2% H1N1, 2.3% Seasonal, 5.5% both
vaccines p0.468. 4 (0.6%) people in the H1N1 only group received hospital treat-
ment, 1 (0.8%) in the seasonal only group and 2 (0.9%) receiving both vaccines. Time
off work (absenteeism), in relation to flu like symptoms, also showed no significant
difference between the groups – 1.7% H1N1, 1.9% Seasonal, 3.4% both vaccines
p0.486. CONCLUSIONS: This evaluation shows that the PROBE methodology
quickly and simply captured patient reported outcome information on resource
utilisation and absenteeism in a vaccinated population. People receiving the H1N1
vaccination alone were more likely to experience side effects than seasonal influ-
enza vaccination alone but this did not lead to a significant increase in resource
utilisation or time off work.
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OBJECTIVES:To describe the key financial resources allocation supporting the HIV/
AIDS prevention, treatment, and social support programs in Thailand and to iden-
tify facilitators and barriers in financial management and monitoring system.
METHODS: Based on a comprehensive review of financial reports from various
sources such as UNGASS, NASA and NAMC reports, we explored the key financial
resources that support the HIV/AIDS prevention, treatment, and social support
programs in Thailand. In addition, we conducted in-depth interviews with differ-
ent key informants responsible for the activities in response to the national policy
on HIV/AIDS in provincial and district levels including domestic and international
donors to assess the financial management, coordination and monitoring system.
RESULTS: The total expenditure on HIV/AIDS in fiscal years 2007, 2008 and 2009
were 204, 210, and 218 million US$, respectively. The national HIV/AIDS spending
was amount to 2.7% (2007) and 1.9% (2008 and 2009) of the total health expenditure.
Domestic funding accounted for 83%, 85% and 93% of the HIV/AIDS programs in
2007, 2008 and 2009. Much of those spending emphasized on care and treatment
while prevention budgeted for 14.1%, 21.7%, and 13.7%. The majority of treatment
financing came from public health insurance schemes, but most preventive pro-
grams were from GFATM and other international sources. Effective system devel-
opment in program management, monitoring and evaluation are still lacking
among practitioners. CONCLUSIONS: Thailand has shown its potential to be self-
reliant in combating HIV/AIDS. Nevertheless, care and treatment expenditures
overshadow prevention, and most of the preventive programs are from interna-
tional sources. Thus, the dominance of entitlement programs in funding for HIV/
AIDS treatment challenges policy makers to monitor the extent and quality of
HIV/AIDS care. For future savings in the cost of treatment and care, investing in
prevention programs is essential, especially due to the declining support from
international funds.
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OBJECTIVES: One in four HIV infected patients is unaware of his condition, and
implies a threefold increase in the risk of HIV transmission. To describe the out-
comes, users’ socio-demographic characteristics and test acceptance of a new
rapid HIV antibody screening test programme offered at Basque community
pharmacies. METHODS: Cross-sectional study based on the answers given by the
users of the rapid HIV antibody screening test, to a questionnaire. The programme
was performed in 20 community pharmacies. Data shown come from a random
sample of the 3514 tests carried out in the first year of the programme. Data gath-
ered include test outcomes, users’ socio-demographic information, their HIV risk
profile, the reasons for asking for the test, and why they chose community phar-
macies to have the HIV test. Statistical analyses included exact tests. RESULTS:
There were 806 valid questionnaires, the mean age of test users was 36.2 years (SD:
11.0; range: 16-82; 71% men). 7 HIV test outcome were positive (0.85%; 95%CI: 0.34 to
1.75), 5 out of them were men. Only 10% of test users came from another country.
Users’ risk behaviour was predominantly heterosexual and 1 in 5 users asked for
the test in the following three months after the exposure to the risk factor, when
the test is not still accurate. More than half of the users hadn’t had a previous HIV
test. The reasons for choosing this kind of HIV test were mainly its quickness (just
15 minutes), and the convenience and rapid access to a community pharmacy
service. The cost of each test for the Basque Government in 2010 was 18.15€
(1887.57€ to detect a positive one). CONCLUSIONS: This new rapid HIV antibody
screening test in community pharmacies can supplement other HIV screening
programs running as the user profile partially differs from them.
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OBJECTIVES: Tobramycin inhaled solution (TIS) has been shown to preserve lung
function in cystic fibrosis (CF) patients chronically infected with Pseudomonas
aeruginosa. To minimize the emergence of aminoglycoside resistant P. aeruginosa
strains, a chronic intermittent treatment of 28 days on and 28 days off TIS is rec-
ommended. The objective of this study was to assess TIS utilization modalities in
CF patients. METHODS: Patients covered by the provincial public drug reimburse-
ment program who had used TIS (Tobi™) on at least one occasion during the period
from January 1, 2007 to December 31, 2008 were selected. To be included in the
study they needed to be cover by the drug program for at least one year after the
initiation of TIS. Patient’s characteristics and drug utilization patterns were ana-
lyzed. For each patient, the number of 28 days periods for which they received TIS
was estimated RESULTS: There were a total of 72 patients who have use TIS during
the study period and were covered by the drug plan for at least one year after the
initiation of TIS. The average age of TIS users was 25.6 years, with a similar pro-
portion of males (51.4%) and females (48.6%). A large proportion of these patients
(40,3%) had diabetes. In the first year following the initiation of TIS, different pat-
terns of utilization were observed: For 15.3% of these patients, TIS was use as a
continuous treatment (42 weeks or more of treatment), 41.7% received 4 cycles or
more, 22.2% received 2 or 3 cycles and 20.8% received only 1 cycle of TIS during the
year. CONCLUSIONS: In this sample, the utilization of TIS in CF patients was sub-
optimal. TIS was used as recommended, as a chronic intermittent treatment by
less than half of the study population.
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OBJECTIVES: Chronic infection with Hepatitis C virus is causing advanced liver
disease in a large proportion of patients. Standard treatment is antiviral therapy
with the goal of a sustained virological response (SVR). The objective of the study is
to validate SVR in the chronic infection Hepatitis C as patient relevant endpoint as
defined by German code of social law. METHODS: Systematic literature searches
were conducted in order to find relevant methods for the validation of surrogate
endpoints in general and to find studies with appropriate data to perform the
validation of SVR as a surrogate parameter in Hepatitis C. The validation will be
realised with the best method according to the data available from the selected
studies. RESULTS: Five studies were identified as basis for validation (out of 694
papers retrieved and 36 studies selected for further analysis). Due to the lack of
long-term studies fulfilling the defined inclusion criteria, no differentiation be-
tween antiviral treatment schemes and different stages of the disease were possi-
ble. Methods of Prentice were identified as applicable for validation. With the four
Prentice criteria, SVR could be validated as a surrogate endpoint for the endpoints
liver cancer and mortality. However, this was not possible with data from all five
studies and only partly with different analysis methods (combination) of data. For
regression models or meta-analysis, data is not sufficient since individual patient
data was not available. For one study further analysis (proportion of treatment
effect) could be performed. CONCLUSIONS:When focussing on statistical methods
current data allows for a very limited validation of SVR as a patient-relevant end-
point for treatment of Hepatitis C, only. There is a lack of long-term data (going
beyond 5 years of follow up), especially for individual data of treated and untreated
patients, likely due to the slow-evolving character of Hepatitis C.
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OBJECTIVES: Seasonal influenza policy in the UK is directed to the elderly and
selected high-risk groups. The department of Health Policy suggests that these
individuals should be vaccinated every year to avoid possible costly or life-threat-
ening complicationsTo define a cost-effectiveness modelling approach and struc-
ture that reflects the season-to-season impact of influenza on the entire UK popu-
lation, and the consequences of policyMETHODS:A structured, iterative, literature
review and analysis of seasonal influenza models RESULTS: Fifty-four references
were reviewed, 32 were assessed. The vast majority of models are decision trees,
considering one influenza season; however, if unit of outcome was life years or
QALYs, impact of influenza mortality was incorporated as average life-expectancy
foregone. Nine models considered healthy and at-risk paediatric populations, six
were UK models of which three papers considered treatment only and the remain-
ing considered treatment and prevention. Ten models reviewed healthy working
adult populations only, two were UK models, one considering prevention, the other
treatment. Sixteen other models reviewed adult populations (healthy and/or at-
risk adults, excluding healthy working adults), nine were UK models. Eleven papers
considered treatment only, two considered prevention only and the remaining
considered treatment and prevention. Twenty-one models evaluated the elderly,
including residential populations. Nine were UK papers; five considered treatment
only and four considered treatment and prevention. CONCLUSIONS: No study as-
sessed the cost-effectiveness in the entire population, only sub-group analyses
have been performed. None of the studies considered the impact of policy options
over multiple consecutive flu seasons during a lifelong time horizon, and – as a
consequence – were not able to incorporate accumulated (Quality Adjusted) Life
Years gained for various age groups. Our suggested approach is a one-year cycle
length, life-time, multi-cohort, Markov model from the perspective of the NHS,
with cohorts starting in different age groups and accounting for at-risk popula-
tions.
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OBJECTIVES: Development of a unique database using data from studies con-
ducted during the vaccine development and its post-marketing to evaluate the
safety profile of a virosomal aluminium-free hepatitis A vaccine in a large
population. METHODS: Available data from various studies, retrieved either from
paper or electronic files, were evaluated and harmonized in order to be combined in
a single database and all adverse events, concomitant diseases and concomitant
vaccinations underwent a new coding. RESULTS: Initial data were available from 3
distinct sources, totalizing 35 studies: individual and summary data from clinical
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